Sun Pharma gets U.S. FDA nod for Prevacid generic drug

MUMBAI Sun Sep 15, 2013 12:18pm IST

A worker stocks shelves at a temporary CVS store in the Rockaway Beach neighborhood of Queens, New York, November 13, 2012. REUTERS/Brendan McDermid/Files

A worker stocks shelves at a temporary CVS store in the Rockaway Beach neighborhood of Queens, New York, November 13, 2012.

Credit: Reuters/Brendan McDermid/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd (SUN.NS) said its unit has received U.S. Food and Drug Administration's (USFDA) final approval for the generic version of Prevacid.

The approval is for Lansoprazole Delayed-Release Capsules USP, 15 and 30 mg, which are therapeutic equivalents of Takeda Pharmaceutical Co. Ltd's capsules, the company said in a release late on Saturday.

The capsules have annual sales of $430 million in the United Sates, it said.

The capsules are used for short-term treatment for healing and symptom relief of active duodenal ulcer, it said.

(Reporting by Subhadip Sircar; Editing by Robert Birsel)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Everest Tragedy

Everest Tragedy

Search ends for missing on Everest, some Sherpas call for shutdown.  Full Article 

Ukraine Crisis

Ukraine Crisis

Deadly gun attack in eastern Ukraine shakes fragile Geneva accord.  Full Article 

Hamilton Wins

Hamilton Wins

Lewis Hamilton wins Chinese GP in Mercedes one-two.  Full Article 

Monte Carlo Masters

Monte Carlo Masters

Wawrinka beats Federer to win Monte Carlo Masters.  Full Article 

Happy Easter

Happy Easter

Pope presides at Vatican Mass leading Catholics into Easter.  Full Article 

Box Office

Box Office

'Captain America' soars again, tops 'Rio 2' to win U.S. box office.  Full Article 

Bollywood

Bollywood

Movie Review: 2 States.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage